-
Deferasirox
- indication:For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
- pharmacologypharmacology:
- mechanism: Deferasirox works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys.
- toxicity:
- absorprion: The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
- halflife: The mean elimination half-life ranged from 8 to 16 hours following oral administration.
- roouteelimination: Deferasirox and metabolites are primarily (84% of the dose) excreted in the feces. Renal excretion of deferasirox and metabolites is minimal (8% of the administered dose).
- volumedistribution: * 14.37 ± 2.69 L
- clearance: